Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GDC-0134 Formulations in Healthy Females
NCT03807739Phase 1Completed
- Sponsor
- Genentech
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of GDC-0134 in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Concentration at 504 hours and Area Under the Curve Extrapolated to Infinity at 504 hours. Started Feb 2019; status: completed.
02
Drugs
GDC-0134
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03807739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807739.